Hormone Therapy and its Effect on the Prognosis in Breast Cancer Patients
| Autor: | Jörg Heil, Julia Kathrin Jueckstock, A. Hartmann, Ruediger Schulz-Wendtland, Peter A. Fasching, Elmar Stickeler, Lothar Häberle, Alexander Hein, M Orlowska-Volk, M. Windfuhr-Blum, C. Sohn, Brigitte Rack, Joachim Rom, Ulrich Andergassen, Maximilian Klar, M. W. Beckmann, Florian Schuetz, Wolfgang Janni, Tanja Fehm, Christian R. Loehberg, Claudia Rauh |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Gynecology medicine.medical_specialty Proportional hazards model medicine.drug_class business.industry medicine.medical_treatment Confounding Obstetrics and Gynecology medicine.disease Article Breast cancer Hormone receptor Estrogen Internal medicine Maternity and Midwifery medicine Hormone therapy business Grading (tumors) Cohort study |
| Popis: | Introduction: Use of hormone therapy (HT) has declined dramatically in recent years. Some studies have reported that HT use before a diagnosis of breast cancer (BC) may be a prognostic factor in postmenopausal patients. This study aimed to examine the prognostic relevance of HT use before BC diagnosis. Methods: Four BC cohort studies in Germany were pooled, and 4492 postmenopausal patients with HT use data were identified. Patient data and tumor characteristics were compared between users and nonusers, along with overall survival (OS), distant metastasis-free survival (DMFS), and local recurrence-free survival (LRFS). Cox proportional hazards models were stratified by study center and adjusted for age at diagnosis, tumor stage, grading, nodal status, and hormone receptors. Results: Women with HT use before the diagnosis of BC were more likely to have a lower tumor stage, to be estrogen receptor–negative, and to have a lower grading. With regard to prognosis there were effects seen for OS, DMFS and LRFS, specifically in the subgroup of women with a positive hormone receptor. In these subgroups, BC patients had a better prognosis with previous HT use. Conclusions: HT use before a diagnosis of BC is associated with a more favorable prognosis in women with a positive hormone receptor status. It may be recommended that the prognostic factor HT should be documented and analyzed as a confounder for prognosis in studies of postmenopausal hormone-responsive breast cancers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|